Company Profile
Coherus BioSciences, Inc. Stock Price, News & Analysis
- Ticker:
- CHRS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.26 USD (-12.76%)
Close
Last updated: August 6, 2026
234M USD
Market cap
Why the stock is moving
Following the latest company update, “Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update”, CHRS closed down 12.8% at $1.26 on Aug 6, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Immuno-Oncology Portfolio
Coherus Oncology develops antibody-based cancer therapies intended to overcome immune suppression in the tumor microenvironment. Its pipeline combines internally controlled candidates with toripalimab, marketed in the United States as LOQTORZI.
Casdozokitug
Casdozokitug is an anti-IL-27 antibody being studied with LOQTORZI in first-line hepatocellular carcinoma. The program targets IL-27-mediated immune suppression and is being evaluated in a randomized Phase 2 trial.
Tagmokitug
Tagmokitug is a CCR8-directed antibody designed to selectively deplete regulatory T cells in tumors. Combination studies with toripalimab span head and neck, upper gastrointestinal, esophageal and colorectal cancers.
Future catalysts
Initial data from the first-line HCC Phase 2 study of casdozokitug around mid-2026.
Initial Phase 1b tagmokitug combination data in second-line head and neck and upper gastrointestinal cancers in mid-2026.
First tagmokitug combination data in esophageal squamous-cell carcinoma in the second half of 2026.
Initial tagmokitug combination data in late-line colorectal cancer in the second half of 2026.
Recent news
- 01
Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update
Source: Coherus BioSciences, Inc.
- 02
Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026
Source: Coherus BioSciences, Inc.
- 03
Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)
Source: Coherus BioSciences, Inc.
- 04
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update
Source: Coherus BioSciences, Inc.
- 05
Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026
Source: Coherus BioSciences, Inc.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Coherus BioSciences, Inc. (CHRS)?
Coherus BioSciences, Inc. (CHRS) most recently closed at 1.26 USD, a -12.76% move versus the previous session.
What is the market cap of Coherus BioSciences, Inc. (CHRS)?
Coherus BioSciences, Inc. currently has a market capitalization of 234M USD on BioPharmSignal.
What does Coherus BioSciences, Inc. do?
Immuno-Oncology Portfolio Coherus Oncology develops antibody-based cancer therapies intended to overcome immune suppression in the tumor microenvironment. Its pipeline combines internally controlled candidates with toripalimab, marketed in the United States as LOQTORZI. Casdozokitug Casdozokitug is an anti-IL-27 antibody being studied with LOQTORZI in...
On which exchange is CHRS stock listed?
Coherus BioSciences, Inc. (CHRS) is associated with NASDAQ, United States, Biopharma.
What is IL-27?
Casdozokitug Casdozokitug is an anti-IL-27 antibody being studied with LOQTORZI in first-line hepatocellular carcinoma.
Which conditions is Coherus BioSciences, Inc. targeting with IL-27?
Coherus BioSciences, Inc. is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Coherus BioSciences, Inc. describe recent progress with IL-27?
Initial data from the first-line HCC Phase 2 study of casdozokitug around mid-2026. Initial Phase 1b tagmokitug combination data in second-line head and neck and upper gastrointestinal cancers in mid-2026. First tagmokitug combination data in esophageal squamous-cell carcinoma in the second half of 2026. Initial tagmokitug combination data in late-line...
What is toripalimab?
Its pipeline combines internally controlled candidates with toripalimab, marketed in the United States as LOQTORZI.